These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

705 related items for PubMed ID: 16456257

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum Beta-lactamase producing Enterobacteriaceae in urinary isolates.
    Afridi FI, Farooqi BJ.
    J Coll Physicians Surg Pak; 2012 Jun; 22(6):358-62. PubMed ID: 22630093
    [Abstract] [Full Text] [Related]

  • 4. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S, Hanaki H, Nagayama A.
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK, Mendes RE, Silbert S, Bolsoni AP, Sader HS.
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
    Xiao YH, Hu YJ.
    Zhonghua Nei Ke Za Zhi; 2017 Aug 01; 56(8):595-600. PubMed ID: 28789493
    [Abstract] [Full Text] [Related]

  • 13. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM, Ueno Y, Cunha BA.
    Chemotherapy; 1996 Aug 01; 42(5):334-42. PubMed ID: 8874972
    [Abstract] [Full Text] [Related]

  • 14. Comparative in vitro activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients.
    Frank U, Mutter J, Schmidt-Eisenlohr E, Daschner FD.
    Clin Microbiol Infect; 2003 Nov 01; 9(11):1128-32. PubMed ID: 14616732
    [Abstract] [Full Text] [Related]

  • 15. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
    Higgins PG, Wisplinghoff H, Stefanik D, Seifert H.
    Antimicrob Agents Chemother; 2004 May 01; 48(5):1586-92. PubMed ID: 15105109
    [Abstract] [Full Text] [Related]

  • 16. Sensitivity pattern of gram negative bacilli to three beta-lactam/beta-lactamase inhibitor combinations using the automated API system.
    Anuradha K, Sailaja VV, Umabala P, Satheesh T, Lakshmi V.
    Indian J Med Microbiol; 2007 Jul 01; 25(3):203-8. PubMed ID: 17901635
    [Abstract] [Full Text] [Related]

  • 17. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).
    Eliopoulos GM, Klimm K, Ferraro MJ, Jacoby GA, Moellering RC.
    Diagn Microbiol Infect Dis; 1989 Jul 01; 12(6):481-8. PubMed ID: 2560420
    [Abstract] [Full Text] [Related]

  • 18. Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI.
    Taneja N, Rao P, Arora J, Dogra A.
    Indian J Med Res; 2008 Jan 01; 127(1):85-8. PubMed ID: 18316858
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity of cefoperazone-sulbactam combination against gram negative bacilli.
    Poudyal N, Gyawali N, Gurung R, Bhattarai NR, Baral R, Khanal B, Shrestha S, Amatya R, Bhattacharya SK.
    Nepal Med Coll J; 2012 Mar 01; 14(1):5-8. PubMed ID: 23441486
    [Abstract] [Full Text] [Related]

  • 20. Piperacillin tazobactam compared with co-amoxiclav, ampicillin plus sulbactam and timentin against beta-lactamase-producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca.
    Traub WH, Leonhard B.
    Chemotherapy; 1995 Mar 01; 41(5):345-52. PubMed ID: 8521736
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.